A5033266569- Monoclonal and Polyclonal Antibodies Research
- Chronic Lymphocytic Leukemia Research
- Rheumatoid Arthritis Research and Therapies
- Systemic Lupus Erythematosus Research
- Inflammatory Bowel Disease
- Colorectal Cancer Treatments and Studies
- Lymphoma Diagnosis and Treatment
- Cancer Treatment and Pharmacology
- Biosimilars and Bioanalytical Methods
- Immunodeficiency and Autoimmune Disorders
- Microscopic Colitis
- HER2/EGFR in Cancer Research
- Blood groups and transfusion
- Renal Transplantation Outcomes and Treatments
- Spondyloarthritis Studies and Treatments
- Complement system in diseases
- Autoimmune and Inflammatory Disorders Research
- Lung Cancer Treatments and Mutations
- Psoriasis: Treatment and Pathogenesis
- Protein purification and stability
- Cancer Immunotherapy and Biomarkers
- Adenosine and Purinergic Signaling
- Vasculitis and related conditions
- Platelet Disorders and Treatments
- Glycosylation and Glycoproteins Research
Université de Tours
2016-2025
Centre Hospitalier Universitaire de Tours
2016-2025
Inserm
2011-2025
University of Basel
2021-2024
University Children’s Hospital Basel
2021-2024
Centre National de la Recherche Scientifique
2011-2023
Canadian Nautical Research Society
2009-2023
Centre Hospitalier Universitaire d'Angers
2022
Centre Hospitalier Universitaire de Rennes
2022
Centre Hospitalier Universitaire de Nantes
2022
The only treatment available to restore normal cardiac output in patients with hereditary hemorrhagic telangiectasia (HHT) and failure is liver transplant. Anti-vascular endothelial growth factor treatments such as bevacizumab may be an effective treatment.To test the efficacy of reducing high severe hepatic forms HHT assess improvement epistaxis duration quality life.Single-center, phase 2 trial national recruitment from French Network. Patients were 18 70 years old had confirmed HHT,...
Infliximab, a chimeric monoclonal antibody, has profoundly modified the treatment of several inflammatory diseases, but no satisfactory description its pharmacokinetics is available. The objective this study to describe infliximab and explore sources interindividual variability. Thirty-three chronic bowel disease patients were studied. Infliximab serum concentrations, obtained during therapeutic drug monitoring, analyzed using population approach. Influence sex, weight, age, concomitant...
A proportion of patients receiving infliximab have antibodies toward (ATI), which are associated with increased risk infusion reaction and reduced response to treatment. We studied the association concentration at treatment initiation development ATI as well presence maintenance infliximab. All rheumatoid arthritis (RA) or spondyloarthritis (SpA) beginning in December 2005 were retrospectively followed until January 2009 discontinuation. Trough serum concentrations measured each visit. The...
Cetuximab is an anti-epidermal growth factor receptor monoclonal antibody used in the treatment of colorectal and head neck cancers. Part interindividual differences response may be explained by variability pharmacokinetics. An assay measuring cetuximab serum concentrations therefore needed. enzyme-linked immunosorbent was developed using microtiter plates sensitized with a recombinant human epidermal extracellular domain. Lower upper limits quantitation limit detection were determined....
Abstract Purpose: An ancillary phase II study was conducted to interindividual variability in cetuximab pharmacokinetics and its influence on progression-free survival (PFS) metastatic colorectal cancer patients cotreated with irinotecan 5-fluorouracil. Experimental Design: Ninety-six received as an infusion loading dose of 400 mg/m2 followed by weekly infusions 250 mg/m2. Doses 5-fluorouracil were adjusted individually. Cetuximab concentrations measured ELISA. Compartmental pharmacokinetic...
The annual cost of eculizumab maintenance therapy in paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic–uremic syndrome (aHUS) exceeds $300,000 per patient. A better understanding pharmacokinetics subsequent individual dose adjustment could reduce this cost. We measured the trough concentration 9 patients with (aHUS, n = 7; PNH, 2) determined: 1) intra- inter-individual variability; influence weight on pharmacokinetics; 3) rate elimination following discontinuation....
Aims This study aimed at describing adalimumab pharmacokinetics ( PK ) and the concentration–effect relationship of using pharmacokinetic–pharmacodynamic PK–PD modelling in patients with rheumatoid arthritis RA ). Methods Adalimumab data were obtained from a multicentric observational study. (40 mg) was administered subcutaneously every other week, its described one‐compartment model. The between concentration C ‐reactive protein CRP an indirect response model inhibition input, whereas...
Infliximab, an anti-tumour necrosis factor-α monoclonal antibody, is indicated in rheumatoid arthritis (RA). Our objective was to evaluate the influence of sources infliximab pharmacokinetic variability RA.Eighty-four patients treated with for RA were included a prospective noncomparative study. They analysed between two consecutive infusions. Infliximab concentrations measured before infusion, 2 h, 1 and 4 weeks after infusion immediately next infusion. described using two-compartment...
Importance There are conflicting data on the association of antidrug antibodies with response to biologic disease–modifying antirheumatic drugs (bDMARDs) in rheumatoid arthritis (RA). Objective To analyze treatment for RA. Design, Setting, and Participants This cohort study analyzed from ABI-RA (Anti-Biopharmaceutical Immunization: Prediction Analysis Clinical Relevance Minimize Risk Immunization Rheumatoid Arthritis Patients) multicentric, open, prospective patients RA 27 recruiting centers...
An enzyme-linked immunosorbent assay (ELISA) measuring serum infliximab concentrations in treated patients was developed. Microtiter plates were sensitized with tumor necrosis factor α (TNF-α) and saturated phosphate-buffered saline (PBS) containing 1% bovine albumin (BSA). Samples diluted 1:100 PBS-1% BSA added bound detected using peroxidase-conjugated goat anti-human immunoglobulin G specific for Fc fragment (HRP-anti hIgG). Reading performed an ELISA plate reader. The limit of detection,...
Infliximab is a chimeric monoclonal antibody that binds to human tumor necrosis factor alpha and approved for refractory rheumatoid arthritis. We studied the association between infliximab concentration long-term control of disease activity in patients with arthritis treated on routine basis both cross-sectional analysis over long term. Trough serum concentrations were measured receiving infusions during period August October 2006. Disease was assessed by Activity Score 28 Joints (DAS28)...
Abstract Because IgG1 allotypes might have different half-lives, their influence on infliximab (G1m17,1 allotype) pharmacokinetics was investigated in a group of spondyloarthritis patients. Infliximab found to shorter half-life patients homozygous for the G1m17,1 than those carrying G1m3 with no G1m1 (G1m3,-1) allotype. neonatal FcR (FcRn) is involved mAbs, interaction FcRn examined using cellular assays and surface plasmon resonance. such as rituximab, were shown bind more efficiently be...
Infliximab is an anti-tumor necrosis factor monoclonal antibody approved in chronic inflammatory diseases such as rheumatoid arthritis (RA), psoriatic (PsA), ankylosing spondylitis (AS), Crohn's disease (CD) and ulcerative colitis (UC). pharmacokinetics variable between patients, but influence of the underlying was never assessed. This study aimed at assessing this using a cohort patients monitored single center with same assay. trough concentrations were determined on samples collected...
Anti-drug antibodies (ADA) are responsible for decreased adalimumab efficacy in axial spondyloarthritis (SpA). We aimed to evaluate the ability of methotrexate (MTX) decrease immunisation.A total 110 patients eligible receive 40 mg subcutaneously (s.c.) every other week were randomised (1:1 ratio) receive, 2 weeks before (W-2) and weekly, MTX 10 s.c. (MTX+) or not (MTX-). ADA detection serum concentration assessed at 4 (W4), 8 (W8), 12 (W12) 26 (W26) after starting (W0). The primary outcome...
Fatal anaphylactic reactions to cetuximab remain a clinical issue, although they are associated with preexisting immunoglobulin E (IgE) directed against the galactose-α1,3-galactose epitope (α3Gal). We aimed compare usefulness of two assays and determine prevalence anti-α3Gal IgE. An IgE assay was developed (70BP assay) compared commercial [bovine thyroglobulin (bTG) assay]. Both were applied cohorts: 299 healthy blood donors 41 patients head neck cancer treated cetuximab, including four...